Clinical Cases in Gastrointestinal Stromal Tumors

In the interview, Alexander Helfand, MD reviewed the latest in gastrointestinal stromal tumor research, and hopes for the future.

After more than 2 years without, the FDA has approved a companion diagnostic to identity candidates for treatment with avapritinib.

In an interview with Targeted Oncology, Antonio Ucar, MD, discussed the evolving role of sunitinib for the second-line treatment of gastrointestinal stromal tumors, and the Peak study.

ctDNA sequencing can efficiently detect KIT/PDGFRA mutations and predict outcomes in patients with tyrosine kinase inhibitor-resistant gastrointestinal stromal tumor treated with avapritinib.

THE-630 will no longer be developed for patients with GIST after patients treated at the 27 mg dose experienced dose-limiting toxicities.

In an interview with Targeted Oncology, Jonathan C. Trent, MD, PhD, discussed primary and offshoot analysis data from the INTRIGUE study of patients with GIST.